Previous 10 | Next 10 |
TEL AVIV, Israel , July 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Inju...
Therapix Biosciences (NASDAQ: TRPX ) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and warrants to purchase up to 2.6M ADSs in a private placement. More news on: Therapix Biosciences Ltd., Therapix Biosciences Ltd AD...
TEL-AVIV, Israel , June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive ...
Gainers: Yunhong CTI (NASDAQ: CTIB ) +88% . More news on: Yunhong CTI Ltd., Immuron Limited, Hertz Global Holdings, Inc., Stocks on the move, , Read more ...
Wah Fu Education Group (NASDAQ: WAFU ) -20% . More news on: Wah Fu Education Group Limited, Therapix Biosciences Ltd., Tarena International, Inc., Stocks on the move, , Read more ...
TEL AVIV, Israel , May 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has closed a joint venture transac...
TEL AVIV, Israel , May 7, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A....
TEL AVIV, Israel , April 22, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the appointment of Mr. Gilad Bar-Lev ...
TEL AVIV, Israel , April 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced the pricing of a public offering for the...
TEL AVIV, Israel , March 25, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that the Company will host a conference call on...
News, Short Squeeze, Breakout and More Instantly...
Therapix Biosciences Ltd. Company Name:
TRPX Stock Symbol:
NASDAQ Market:
TEL AVIV, Israel , Aug. 21, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the replacement of its board of directors. The Comp...
TEL AVIV, Israel , July 9, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that its American Depositary Shares ("ADSs") will no...
TEL AVIV, Israel , July 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Inju...